Although immune checkpoint inhibitors, such as anti-CTLA-4 and PD-1, have demonstrated promising anti-tumor effects in the clinical treatment of melanoma, a subset of patients does not respond to these immunotherapeutic agents. Here, CTLA4 is linked to melanoma.